Intellia's Hereditary Angioedema Candidate Shows Reduction In Associated Biomarkers, Attack Rates

• Intellia Therapeutics Inc (NASDAQ: NTLA) announced updated data from an ongoing Phase 1/2 study of NTLA-2002 for hereditary angioedema (HAE).

• Single doses of 25 mg (n=3), 50 mg (n=4), and 75 mg (n=3) of NTLA-2002 were administered via intravenous infusion.

• Administration of NTLA-2002 led to deep, dose-dependent reductions in plasma kallikrein.

• For the 25 mg and 75 mg cohorts, these deep reductions in plasma kallikrein were sustained through the observation period, which ranged from week 16 to week 32.

• Related: Intellia Therapeutics Posts Back To Back Positive Data From Gene Editing Therapies.

• All patients treated in the 25 mg and 75 mg cohorts have an ongoing attack-free interval through the latest follow-up.

• The first three patients treated have an ongoing attack-free interval of 5.5 – 10.6 months after a single dose of NTLA-2002.

• At all three dose levels, NTLA-2002 was generally well-tolerated, and the majority of adverse events were mild in severity.

• Intellia expects to select up to two doses to further evaluate NTLA-2002 in the Phase 2 study, which is expected to begin in 1H of 2023.

• Price Action: NTLA shares closed higher by 4.17% at $54.95 on Friday.

See more from Benzinga

• Ascendis Pharma's Program Hits Primary Goal In Children With Short-Limbed Dwarfism

• RBC Capital Initiates Coverage On This MedTech Stock Citing 'Differentiated Offering'

• Elon Musk Asked A Top Tesla Executive To Forfeit Unvested Equity Awards And He Promptly Quit: Report - Te

Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.